DYN - Dyne Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$35.50
DETAILS
HIGH:
$47.00
LOW:
$24.00
MEDIAN:
$35.50
CONSENSUS:
$35.50
UPSIDE:
45.25%
About Dyne Therapeutics, Inc. (https://www.dyne-tx.com)
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| John G. Cox | Chief Executive Officer, President & Director | 1963 | $1,138,975 USD |
| Johanna Friedl-Naderer | Chief Commercial Officer | 1968 | $842,754 USD |
| Douglas Kerr | Chief Medical Officer | 1967 | $748,065 USD |
| Oxana Beskrovnaya | Chief Innovation Officer | 1961 | $740,475 USD |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | 1968 | $726,892 USD |
| Axel Wiest | Senior VP and Head of Portfolio Strategy & Operations | – | – |
| Daniel Wilson | Senior Vice President & Head of Legal | 1972 | – |
| Debra Feldman | Chief Regulatory Affairs Officer | 1971 | – |
| James Bilotta | Chief Digital & Information Officer | – | – |
| Lucia Celona | Chief Human Resource Officer | 1966 | – |
| Rajesh Manchanda | Chief Technical Officer | 1967 | – |